The following article features coverage from the American Society of Clinical Oncology 2020 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

A chemotherapy regimen that is standard in the United States for patients with Ewing sarcoma appeared to improve outcomes compared with a chemotherapy regimen that is standard in Europe, the phase 3 Euro Ewing 2012 trial found. The trial results were reported at the ASCO20 Virtual Scientific Meeting.

A total of 640 patients from 112 clinical sites outside of the US were randomized to receive either the chemotherapy regimen that was standard in Europe or the chemotherapy regimen that was standard in the US.

The European regimen was a VIDE strategy, consisting of induction chemotherapy with VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) followed by consolidation chemotherapy with 1 cycle of VAI (vincristine, actinomycin D, and ifosfamide) and 7 cycles of VAC (vincristine, actinomycin D, or cyclophosphamide) or 8 cycles of VAI.

The US regimen was a VDC/IE strategy, consisting of induction chemotherapy with alternating cycles of VDC (vincristine, doxorubicin, cyclophosphamide) and IE (ifosfamide and etoposide) followed by consolidation chemotherapy with alternating cycles of IE and VC (vincristine and cyclophosphamide).


Continue Reading

Related Articles

At a median follow-up of 1.7 years, patients who received the VDC/IE strategy had a prolonged event-free survival (EFS; hazard ratio [HR], 0.66; 95% CI, 0.49-0.90) and overall survival (OS; HR, 0.64; 95% CI, 0.43-0.94) compared with patients who received the VIDE strategy.

This trend of improved EFS and OS with the VDC/IE strategy was seen across subgroups, which included gender, age, disease type, and tumor volume.

The frequency of grade 3 or higher adverse events was similar between the VIDE strategy and VDC/IE strategy during induction chemotherapy (91% vs 90%) and consolidation chemotherapy (65% vs 65%).

“VDC/IE chemotherapy is superior to VIDE for both EFS and OS, with no excess toxicity,” the study authors concluded.

Read more of Cancer Therapy Advisor‘s coverage of the ASCO 2020 meeting by visiting the conference page.

Reference

Brennan B, Kirton L, Marec-Berard P, et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). Presented at: ASCO20 Virtual Scientific Program. J Clin Oncol. 2020;38(suppl):abstr 11500.